Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
COPD
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - COPD
    Inhaled Corticosteroids in Patients With Stable Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis - (JAMA)
    Use of Inhaled Corticosteroids for COPD Does Not Appear to Improve Survival, May Increase Risk for Pneumonia - (DGNews)
    TopAbstracts in COPD 11/24/2008 - (DGNews)
    Long-Term Erythromycin Therapy Reduces COPD Exacerbations, but Raises Concerns - (DGNews)
    Preoperative Pulmonary Function Test Provides Accurate Risk Assessment of Complications and Death in Cardiac Surgery Patients: Presented at AHA - (DGDispatch)

    News archive

     Recent webcasts/CME - COPD
    Current Issues in the Management of Respiratory Tract Congestion
    Silica-Related Lung Disease: It's Still Here
    Obesity and Pulmonary Dysfunction

    Webcasts/CME archive

     Recent cases - COPD
      An Unusual Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) with Herpes Simplex Tracheitis: A Case Report
      Home Oxygen Therapy and Cigarette Smoking: A Dangerous Practice
      Failure of Levofloxacin Treatment in Community-Acquired Pneumococcal Pneumonia
      Invasive Pulmonary Aspergillosis Complicating Chronic Obstructive Pulmonary Disease in an Immunocompetent Patient
      Severe Chronic Lung Disease and Respiratory Distress

      Cases archive
        




      my personal edition > copd > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Fluticasone, Salmeterol Combination Increases Survival in Moderate-Severe COPD: Presented at CHEST

      By John Gever

      SALT LAKE CITY, UT -- October 25, 2006 -- Three years of treatment combining a corticosteroid drug with a long-acting beta agonist cut the death rate from chronic obstructive pulmonary disease (COPD) by 17%, according to a large, multinational, placebo-controlled study presented here at CHEST 2006, the annual meeting of the American College of Chest Physicians.

      The data, from the TOward a Revolution in COPD Health (TORCH) study, were presented by Bartolome Celli, MD, professor of medicine, Tufts University, and chief of pulmonary medicine, Caritas-St. Elizabeth's Medical Center, Boston, Massachusetts.

      "I think it is a landmark trial," Dr. Celli said in a press briefing on October 23rd, describing the results at a press briefing prior to the formal presentation.

      Celli noted that in the primary statistical analysis, the mortality reduction fell just short of significance (P = .052). "This is a point of contention," he acknowledged. But Celli said a secondary analysis with Cox's proportional hazards test, which accounts for co-variables such as age, supported the main finding, with a statistically significant P = .031.

      The randomized, double-blind trial involved 6,112 patients with moderate to severe COPD from 42 countries. They received 500 mcg fluticasone proprionate, 50 mcg salmeterol, a combination of the 2 drugs or placebo twice daily for 3 years. The primary outcome measure was death from all causes.

      On an intent-to-treat basis, 15.2% of patients in the placebo group died, versus 12.6% of those assigned to the fluticasone-salmeterol combination. There was no important difference in death rates between placebo and either of the drugs alone.

      The chief adverse effect seen with the combination therapy was hoarseness and thrush. Dr. Celli said the incidence of pneumonia was also increased in the combination group, but without an associated increase in deaths. Pneumonia diagnoses were not confirmed with X-rays and it may be that many were actually less severe respiratory infections.

      Commenting on the study, Ronald Grossman, MD, chief of medicine, Credit Valley Hospital, Mississauga, Ontario, Canada, suggested that the 17% advantage for the combination is probably an underestimate. The extremely rigorous criteria used in the mortality analysis made the placebo results appear better than they really were, he said; most participants who withdrew from treatment were in the placebo group, and most of the dropouts later received active treatment outside the trial. Had they stayed in the trial receiving placebo, it's likely more of them would have died, he said.

      Other analyses of TORCH data were also presented at the meeting, and the researchers reported that the combination decreased the rate of COPD exacerbations and improved health status over 3 years of treatment.

      The fluticasone-salmeterol combination is sold in the U.S. under the name Advair and in Europe as Seretide. In the U.S., the 500/50 dosage is approved for asthma but not COPD. GlaxoSmithKline is the manufacturer and sponsored the TORCH study.


      [Presentation title: The TOward a Revolution in COPD Health (TORCH) Study: Fluticasone Proprionate/Salmeterol Improves Survival in COPD Over Three Years, Abstract 3374]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send